Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism
- PMID: 221531
- PMCID: PMC372026
- DOI: 10.1172/JCI109385
Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism
Abstract
This report describes the effects of pharmacologic doses (3 g/d) of nicotinic acid on the plasma distribution and chemical composition of the high density lipoprotein (HDL) subfractions HDL(2) and HDL(3) and examines the influence of the drug on the metabolism of the major HDL apoproteins, apolipoproteins A-I (ApoA-I) and A-II (Apo-II). The drug lowered plasma cholesterol (15%, P < 0.05) and triglyceride (27%, P < 0.01); the former effect a result of a fall in the amount of cholesterol associated with very low density lipoproteins (31%, P < 0.02) and low density lipoproteins (36%, P < 0.02). Conversely, it raised plasma HDL cholesterol (23%, P < 0.05) and increased (by 345%) the plasma HDL(2):HDL(3) ratio. The latter derived from an absolute increment (646%) in circulating HDL(2), coupled with a fall (47%) in HDL(3). This change was not associated with major alterations in the overall cholesterol (free and esterified), triglyceride, phospholipid, or protein content of the subfractions; however, it was accompanied by substantial changes in their protein composition. In particular, the molar ratio of ApoA-I:ApoA-II in HDL(3) declined from 2.7:1 to 2.1:1 during nicotinic acid treatment.Significant perturbations of ApoA-I and ApoA-II metabolism accompanied the drug-induced HDL subfraction redistribution. Specifically, the plasma concentration of ApoA-I rose by 7% (P < 0.05) because of a decrease in its fractional catabolic rate. Moreover, whereas before treatment 6 and 94% of the plasma ApoA-I circulated with HDL(2) and HDL(3), after commencement of nicotinic acid therapy this distribution became 49 and 51% in HDL(2) and HDL(3), respectively. ApoA-II was found mainly in HDL(3), both before and during nicotinic acid treatment. Administration of the drug caused a 14% reduction in its plasma concentration (P < 0.05), which derived principally from a fall (22%, P < 0.01) in its synthetic rate. These data suggest that the effects of nicotinic acid on the HDL subfraction distribution may be mediated via (a) net transfer of ApoA-I from HDL(3) to HDL(2) and (b) a reduction in ApoA-II synthesis. Our present understanding of the association between HDL and atherosclerosis indicates that such changes may have prophylactic value in the prevention of coronary artery disease.
Similar articles
-
Effects of dietary polyunsaturated and saturated fat on the properties of high density lipoproteins and the metabolism of apolipoprotein A-I.J Clin Invest. 1978 Jun;61(6):1582-92. doi: 10.1172/JCI109078. J Clin Invest. 1978. PMID: 207739 Free PMC article.
-
Effects of niceritrol (pentaerythritol tetranicotinate) on plasma lipoprotein concentration: increment of high density lipoprotein(HDL) cholesterol and HDL-cholesterol/low density lipoprotein cholesterol ratio in hypo-high density lipoproteinemia.Artery. 1982;10(4):266-85. Artery. 1982. PMID: 7181672
-
Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.Am J Cardiol. 2009 Feb 1;103(3):387-92. doi: 10.1016/j.amjcard.2008.09.103. Epub 2008 Nov 27. Am J Cardiol. 2009. PMID: 19166694 Clinical Trial.
-
Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?Am J Cardiol. 2007 Dec 3;100(11 A):S53-61. doi: 10.1016/j.amjcard.2007.09.080. Am J Cardiol. 2007. PMID: 18047854 Review.
-
Plasma lipoproteins and coronary heart disease.Ann Clin Lab Sci. 1978 Mar-Apr;8(2):79-83. Ann Clin Lab Sci. 1978. PMID: 205164 Review.
Cited by
-
GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.J Clin Invest. 2005 Dec;115(12):3634-40. doi: 10.1172/JCI23626. J Clin Invest. 2005. PMID: 16322797 Free PMC article.
-
Gene activation regresses atherosclerosis, promotes health, and enhances longevity.Lipids Health Dis. 2010 Jul 6;9:67. doi: 10.1186/1476-511X-9-67. Lipids Health Dis. 2010. PMID: 20604930 Free PMC article. Review.
-
Niacin: an old drug rejuvenated.Curr Atheroscler Rep. 2009 Jan;11(1):45-51. doi: 10.1007/s11883-009-0007-9. Curr Atheroscler Rep. 2009. PMID: 19080727 Review.
-
Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography.J Lipid Res. 2011 Mar;52(3):566-71. doi: 10.1194/jlr.P011668. Epub 2011 Jan 11. J Lipid Res. 2011. PMID: 21224290 Free PMC article. Clinical Trial.
-
Niacin and analogs for phosphate control in dialysis--perspective from a developing country.Int Urol Nephrol. 2009 Dec;41(4):913-8. doi: 10.1007/s11255-008-9497-6. Epub 2008 Nov 27. Int Urol Nephrol. 2009. PMID: 19037739 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources